StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by KPOIndustrieson Nov 15, 2019 10:06am

89 Views

Post# 30356001

RE:RE:Test numbers

Barrhead wrote: Perhaps mentioned during the CC webcast - I heard there were 500-600 tests/month stated by JT, which translates to the 1500-600/qtr. It might worthwhile listening again to confirm.

Yes, that is the same as prior quarters, which doesn't add up. In the Q3 result newsletter, it states they had 1500 tests for Q3. Not sure where the wheels fell off here, but this is very dissapointing.

Bullboard Posts

Investors eye Australian gold mining projects amid promising developments